Kodiak Sciences upgraded to Neutral from Underweight at JPMorgan

JPMorgan upgraded Kodiak Sciences (KOD) to Neutral from Underweight with a $15 price target The firm says the company is entering a “very catalyst-rich period” over the next two-years with key pivotal data for tarcocimab, KSI-501, and KSI-101. Kodiak shares are likely to perform more in-line with the group and “clear clinical wins” in the studies may be needed to shift investor sentiment, the analyst tells investors in a research note.